Camurus receives second complete response letter for acromegaly drug CAM2029; Teva announces workforce reductions
Camurus reported that the FDA issued a second complete response letter for its investigational acromegaly therapy CAM2029, citing issues related to a third‑party manufacturer.
The agency’s concerns focus on manufacturing deficiencies that must be resolved before the product can proceed in the review process, delaying any potential approval timeline.
In separate news, Teva Pharmaceutical disclosed plans to cut jobs as part of a restructuring effort, though details on the number of positions affected were not provided.
The combined developments underscore ongoing regulatory and operational challenges facing companies in the specialty endocrinology space.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Camurus’ second CRL for acromegaly drug; Teva details workforce cuts”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that